abstract: Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer (Spain)

Conclusions: Combined bevacizumab and metronomic oral cyclophosphamide is a safe and effective regimen for heavily pre-treated ovarian cancer patients. Further research is needed on predictive factors to screen for those patients who will benefit from anti-angiogenic therapy.